Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

Míreanna Comhchosúla

• Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
  le: Dominic Pilon, et al.
  Foilsithe: (2017-06-01)
• Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
  le: Lafeuille, Marie-Hélène, et al.
  Foilsithe: (2018)
• Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
  le: Emond, Bruno, et al.
  Foilsithe: (2018)
• Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
  le: Pilon, Dominic, et al.
  Foilsithe: (2017)
• Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
  le: Pesa, Jacqueline A., et al.
  Foilsithe: (2015)